PDCD1 and skin cancer: Based on this premise, for instance, Dodagatta-Marri et al. (2019) have shown that outcomes obtained with an anti-PD-1 antibody can be improved by combining it with an anti-TGF-β neutralizing antibody treatment in xenograft models of skin cancer.